论文部分内容阅读
Dgnacirc(即Isradipine)是一新型吡啶类钙离子拮抗剂,它为一种强有力的血管扩张剂,但对心脏本身几乎无作用。药品由瑞士山度士公司提供,每片2.5毫克。用于观察对高血压病的治疗效果。15例高血压患者,经临床体检和实验室检查确诊为原发性高血压病,男5,女10,年龄31～68岁,平均54.3±11.5岁,高血压病史3～25年,平均18.7年,用药前血压平均为25.3±3.1/14.7±2.4kPa,合并冠心病3例、糖尿病3例。用药前作血常规,血小
Dgnacirc (Isradipine) is a novel pyridine-based calcium channel blocker that is a potent vasodilator but has little effect on the heart itself. Drugs provided by Switzerland Santos, each 2.5 mg. Used to observe the effect of treatment of hypertension. Fifteen hypertensive patients were diagnosed as primary hypertension by clinical physical examination and laboratory tests. The patients were 5 and 10 years old, ranging in age from 31 to 68 years with an average age of 54.3 ± 11.5 years. The history of hypertension was from 3 to 25 years (mean, 18.7) Years, the average blood pressure before treatment was 25.3 ± 3.1 / 14.7 ± 2.4kPa, with coronary heart disease in 3 cases and diabetes in 3 cases. Before treatment for blood, blood